The short-term impact of Botox injections on speech disability in adductor spasmodic dysphonia.

Ferens Unit, Middlesex Hospital Outpatients Department, London, UK.
Disability and Rehabilitation (Impact Factor: 1.84). 02/1997; 19(1):20-5. DOI: 10.3109/09638289709166441
Source: PubMed

ABSTRACT This study investigates the impact of Botox injections on speech disability in a group of patients with adductor spasmodic dysphonia. Patient-perceived disability was assessed on the Speech Disability Questionnaire. A factor analysis on speech disability yielded five factors. Four of these, social isolation (p < 0.001), negative communication (p < 0.005), public avoidance (p < 0.05) and limited understanding (p < 0.01), showed significant change from prior to and one week post injection. Speech and language therapists' assessment also showed changes in voice quality over the same period. These findings are discussed in terms of the relationship between voice quality, disability and handicap, in adductor spasmodic dysphonia.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study is to examine the psychosocial consequences of BOTOX (Allergan, Inc. Irvine, CA) treatment for spasmodic dysphonia (SD). This article also explores how patients judge the success of treatment and make decisions about future treatment based on psychosocial issues relevant to them. This study follows the phenomenological tradition of qualitative inquiry in which the objective is to explore the lived experiences of a group of persons who share a common phenomenon, in this case receiving BOTOX injections for SD. Six adults with SD who had been receiving BOTOX injections on a long-term basis participated in face-to-face interviews. The interviews were recorded, transcribed, and analyzed according to phenomenological guidelines to identify consistent themes as well as differences among participants' experiences. The results are summarized in three primary themes that suggest (1) participants' experiences vary over time based on changes in factors such as lifestyle and personal priorities; (2) BOTOX has multidimensional psychosocial implications in physical, personal, and social domains; and (3) participants individualize their treatment regimens, taking into consideration the burden of treatment, scheduling priorities, and other strategies to maximize the benefits of BOTOX. Based on this study, suggestions are provided for future research into a psychosocial outcome measurement, including longitudinal evaluations that accommodate changing patient priorities over time; multidimensional evaluations that incorporate physical, personal, and social issues; evaluations that include a measure of the burden of treatment; and evaluations that support a shared decision-making model with the voice clinicians.
    Journal of Voice 04/2007; 21(2):231-47. DOI:10.1016/j.jvoice.2006.01.007 · 0.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the potential of onabotulinum toxin A (Botox®, Allergan, Inc., Irvine, California) in the treatment of restless legs syndrome (RLS). A single-arm, open-label pilot trial of onabotulinum toxin A was conducted to determine its usefulness as an injectable treatment for RLS. The primary outcome measure, change in score on the International Restless Legs Syndrome Scale, showed a statistically significant improvement in RLS during the first 4 weeks after treatment. Two of the secondary outcome measures, pain (measured using a visual analog scale) and patients' global impression of severity of illness also showed improvement. Onabotulinum toxin A warrants further study in RLS. Increasing the drug dosage, changing the dosing schedule, and increasing the number of injection sites may result in greater activity and longer duration of action.
    The International journal of neuroscience 08/2011; 121(11):622-5. DOI:10.3109/00207454.2011.602774 · 1.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review systematically examines the effects of botulinum toxin type A (BTX-A) on patient-reported outcomes across disorders using evidence-based criteria. The evidence provided by these studies ranged from randomized, controlled trials to case series. The effects of BTX-A on quality of life or global treatment outcomes were assessed in 48 studies across 16 different conditions. All but 7 of these reported benefits of BTX-A over baseline or the comparator condition (placebo or other treatment). The effects of BTX-A on impairment, activities, or participation were assessed in 46 studies across 17 different conditions. All but 4 reported benefits of BTX-A over baseline or the comparison group. The effects of BTX-A on satisfaction or preference were assessed in 14 studies across 11 different conditions, all of which reported high rates of satisfaction with BTX-A or preference over the comparator. These studies provide evidence that BTX-A exerts meaningful benefits on the quality of life of patients treated with this biologic agent.
    Clinical Neuropharmacology 01/2004; 27(5):234-44. DOI:10.1097/01.wnf.0000145508.84389.87 · 1.84 Impact Factor